ARE Stock Analysis — Alexandria Real Estate Equities
Sector: REIT
AI Verdict
ARE trades at 197.3x next year's earnings while growth has reversed (-6.8% YoY revenue) and the PEG is 2.27, so you're paying a premium the numbers don't yet support—even with the unique life science moat, the risk of further downside is real if fundamentals don't improve.
Competitive Moat
Alexandria specializes in life science campuses clustered in top biotech hubs, offering lab space that is difficult and expensive for competitors to replicate due to zoning, permitting, and infrastructure barriers. Their tenant base of major pharma and biotech firms creates long-term leases and high switching costs, anchoring occupancy even in downturns.
Summary
The stock is notable for its rare, purpose-built life science real estate portfolio, but faces scrutiny as growth stalls and valuation remains sky-high.
Where It Stands
ARE is down -47.51% over the past year with an RSI of 38.5 signaling near-oversold territory, but still trades at 197.3x forward earnings versus a typical REIT P/E well below 20x.
Key Metrics
- RSI: 38.5 — Near Oversold
- Forward P/E: 197.3x
- PEG Ratio: 2.27
- Revenue Growth: -0.1%
- Market Cap: $7.0B
- Dividend Yield: 0.06%
- 1-Year Return: -47.51%
- 52-Week High: $88.24
- 52-Week Low: $41.44
Analyst Consensus
7 Buy · 14 Hold · 1 Sell (22 analysts)
Bull Case
The RSI of 38.5 suggests the stock is approaching oversold levels, which could attract buyers if sentiment turns.
Bear Case
At 197.3x forward earnings and a PEG of 2.27, even a modest P/E compression toward the sector norm would mean a steep further drop from here.
Catalyst to Watch
Watch for leasing updates or tenant retention rates—any sign of accelerating vacancy or rent pressure could force a major valuation reset.